Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial
Adenocarcinoma Metastatic|Biliary Tract Cancer|Adenocarcinoma of the Biliary Tract|Adenocarinoma Locally Advanced|Non-Resectable Hepatocellular Carcinoma|Intrahepatic Bile Duct Carcinoma|Extrahepatic Bile Duct Carcinoma
DRUG: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|DRUG: Arm Cisplatin + Gemcitabine (Arm B)
Progression-free survival [PFS], approx. 25 months
Overall progression free survival according to RECIST 1.1, Response Evaluation Criteria in Solid Tumors (RECIST 1.1.), approx. 54 months|3-years overall survival, 3-years overall survival, approx. 36 months|Disease control rate according to RECIST 1.1, approx. 54 months|Objective tumor response rate (ORR) according to RECIST 1.1, Proportion of patients with an objective response according to RECIST 1.1, approx. 54 months|Toxicity/Safety according to CTC-AE-criteria, approx. 54 months|Health related quality of life, EORTC QLQ-BIL21, approx. 54 months|Health related quality of life, EORTC QLQ-C30, approx. 54 months|Health related quality of life, Hospital Anxiety and Depression Scale (HADS-D), approx. 54 months|Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review, Tumor resectability in accordance with a retrospective central surgical board compared to local surgical review, approx. 54 months|Retrospective central radiological review, approx. 54 months
Exploratory biomarkers analysis, cfDNA exome sequencing, transcriptome, miRNA-arrays prior to and after start of treatment and upon progress, approx. 54 months|Establishment of Predictive/Prognostic biomarker profiles for advanced cholangiocarcinoma, approx. 54 months|Tumor Evolution under systemic therapy, approx. 54 months
The primary objective is to determine whether a combination of 5-FU and nal-IRI prolongs progression-free survival in patients with locally advanced or metastatic adenocarcinoma of the biliary tract